14-GI-92-LP (LX1606/1-303-CS) Telotristat Etiprate for Carcinoid Syndrome Therapy

Grants and Contracts Details

StatusFinished
Effective start/end date9/22/142/28/18

Funding

  • Lexicon Pharmaceuticals Incorporated: $165,919.00